Repository logo
 
Publication

Protecting Older Patients with Cardiovascular Diseases from COVID-19 Complications Using Current Medications

2021-08Journal article Open access
Simple item page
dc.contributor.authorAlves, M
dc.contributor.authorFernandes, M
dc.contributor.authorBahat, G
dc.contributor.authorBenetos, A
dc.contributor.authorClemente, H
dc.contributor.authorGrodzicki, T
dc.contributor.authorMartínez-Sellés, M
dc.contributor.authorMattace-Raso, F
dc.contributor.authorRajkumar, C
dc.contributor.authorUngar, A
dc.contributor.authorWerner, N
dc.contributor.authorStrandberg, T
dc.contributor.authorEuGMS Special Interest Group in Cardiovascular Medicine
dc.date.accessioned2023-02-13T15:43:58Z
dc.date.available2023-02-13T15:43:58Z
dc.date.issued2021-08
dc.description.abstractPurpose: In the pathogenesis of severe COVID-19 complications, derangements of renin-angiotensin-aldosterone system (RAAS), vascular endothelial dysfunction leading to inflammation and coagulopathy, and arrhythmias play an important role. Therefore, it is worth considering the use of currently available drugs to protect COVID-19 patients with cardiovascular diseases. Methods: We review the current experience of conventional cardiovascular drugs [angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers, anticoagulants, acetosalicylic acid, antiarrhythmic drugs, statins] as well as some other drug classes (antidiabetic drugs, vitamin D and NSAIDs) frequently used by older patients with cardiovascular diseases. Data were sought from clinical databases for COVID-19 and appropriate key words. Conclusions and recommendations are based on a consensus among all authors. Results: Several cardiovascular drugs have a potential to protect patients with COVID-19, although evidence is largely based on retrospective, observational studies. Despite propensity score adjustments used in many analyses observational studies are not equivalent to randomised controlled trials (RCTs). Ongoing RCTs include treatment with antithrombotics, pulmonary vasodilators, RAAS-related drugs, and colchicine. RCTs in the acute phase of COVID-19 may not, however, recognise the benefits of long term anti-atherogenic therapies, such as statins. Conclusions: Most current cardiovascular drugs can be safely continued during COVID-19. Some drug classes may even be protective. Age-specific data are scarce, though, and conditions which are common in older patients (frailty, comorbidities, polypharmacy) must be individually considered for each drug group.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationEur Geriatr Med. 2021 Aug;12(4):725-739.pt_PT
dc.identifier.doi10.1007/s41999-021-00504-5.pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/4405
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherSpringerpt_PT
dc.subjectHCC MEDpt_PT
dc.subjectAgedpt_PT
dc.subjectHumanspt_PT
dc.subjectPandemicspt_PT
dc.subjectAngiotensin Receptor Antagonists / therapeutic usept_PT
dc.subjectAngiotensin-Converting Enzyme Inhibitors / therapeutic usept_PT
dc.subjectCOVID-19 Drug Treatment*pt_PT
dc.subjectCOVID-19 / diagnosispt_PT
dc.subjectCardiovascular Diseases / drug therapy*pt_PT
dc.subjectRenin-Angiotensin System / drug effectspt_PT
dc.subjectSARS-CoV-2 / isolation & purification*pt_PT
dc.subjectSARS-CoV-2 / pathogenicitypt_PT
dc.titleProtecting Older Patients with Cardiovascular Diseases from COVID-19 Complications Using Current Medicationspt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage739pt_PT
oaire.citation.startPage725pt_PT
oaire.citation.titleEuropean Geriatric Medicinept_PT
oaire.citation.volume12pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Eur Geriatr Med 2021.pdf
Size:
692.51 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

END - Artigos